Coronavirus disease is of an urgent global priority. The purpose of ImmuneSense™ COVID-19 study is to evaluate the clinical performance and to provide data for clinical validation for the T-Detect™ SARS-CoV-2 (previously referred to as immunoSEQ Dx SARS-CoV-2) Assay in support of Adaptive's Emergency Use Authorization (EUA) request for T-Detect™ SARS-CoV-2 and secondary aims. This assay is intended to detect immune response to the virus that causes coronavirus disease (COVID-19), SARS-CoV-2. This is critically important because the immune system may be able to tell us important information about how our own bodies detect and respond to the disease that current tests cannot.
Comprehensive diagnostic testing has an important role to play in the control and containment
of the current pandemic. Adaptive Biotechnologies Corporation (Adaptive) has developed an
immunosequencing technology, called immunoSEQ®, which utilizes polymerase chain reaction
(PCR) and next-generation sequencing (NGS) to identify and quantify rearranged T-cell
receptor (TCR) gene sequences from peripheral blood, collectively referred to as the T-cell
repertoire. The T-cell repertoire can be further analyzed using indication-specific
algorithms that are based on disease-associated TCR sequences.
Adaptive has developed a clinical test called T-Detect™ SARS-CoV-2, which is intended to
identify a T-cell response to the SARS-CoV-2 virus, indicating recent or prior infection. In
this investigational study, Adaptive plans to clinically validate samples acquired from
patients with COVID-19 and present results for an eventual EUA-submission for the T-Detect™
SARS-CoV-2 Assay. T-Detect™ SARS-CoV-2 is a single-site assay performed at Adaptive
Biotechnologies Corporation.
Other: T-Detect™ SARS-CoV-2 Assay
T-Detect™ SARS-CoV-2 Assay is an investigational device that is indicated to assess T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19. These results will not be shared with the participant.
Inclusion Criteria
Participants must satisfy the following criteria to be enrolled in the study:
- Currently symptomatic individuals who are being tested for SARS-CoV-2 infection by
nasopharyngeal swab
- Male and female participants of any race and ethnicity between 18 to 89 years of age
(inclusive) at the time of enrolling in the study
- Must be able to communicate with the investigator, understand, and comply with the
requirements of the study
Exclusion criteria
The presence of any of the following will exclude a participant from enrollment:
- Asymptomatic individuals who are being tested for SARS-CoV-2 infection
- Prior confirmed diagnosis of COVID-19
- Any person who cohabitated with another individual with known COVID-19
- Protected populations including minors, pregnant women, prisoners, mentally disabled
persons, and wards-of-the state
- Any significant condition, laboratory abnormality, or psychiatric illness that would
prevent the participant from safely participating in the study
- Donated more than 500cc or 1 pint of blood in the past 60 days prior to the blood draw
- Participation in a COVID-19/SARS-CoV-2 study or received a COVID-19 vaccine, antibody,
or other COVID-19 therapeutic Investigational drug or compound that will impact
results of the study at the discretion of the investigator, such as but not limited to
a COVID-19 antibody, therapeutic, or other medication that will impact the person's
immune system
Adaptive Biotechnologies Clinical Investigational Site
Secaucus, New Jersey, United States
Namita Singh, MD, Study Director
Medical Director, Clinical Development